scholarly journals The Effects of Combined Insulin and Metformin Therapy in Obese Patients with Diabetes Mellits Type 2 in the Early Stage of the Disease

2008 ◽  
Vol 6 (3) ◽  
pp. 61-67
Author(s):  
Emela Mujić-Skikić ◽  
Suad Trebinjac ◽  
Dijana Avdić ◽  
Amra Džumhur-Sarić
Keyword(s):  
Insulin Therapy ◽  
Pancreatic Beta Cells ◽  
Early Stage ◽  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Target Cells ◽  
Obese Patients ◽  
Patients With Diabetes ◽  
Insulin Activity

Combination of insulin and metformin has been shown to improve glycaemic control in clinical trials, particularly in obese patients with diabetes type 2. Insulin therapy can improve function of pancreatic beta cells and periphery insulin activity in target cells in order to enhance glycaemic homeostasis (1, 2, 3). In our study we included obese patients with diabetes type 2 in the early stage of the disease. The study is partially retrospective and partially prospective. The study encompassed 40 patients split in two groups. The first group of 20 patientsreceived insulin therapy combined with metformin, while the patients of the second group were treated with oral antidiabetic drugs, sulfonylureas and metformin. Three months later, the group treated with insulin and metformin showed improvement in the monitored parameters, namely significant reduction in HbA1c (p = 0.003), MFBG (p = 0.0009), PPG (p = 0.028). Insulin therapy administered together with metformin, in obese patients with diabetes type 2, in the early stage of the disease, resulted in well regulated fasting blood glycaemia, as well as post challenge glycaemia and HbA1c.

scholarly journals The Effects of Combined Insulin and Metformin Therapy in Obese Patients with Diabetes Mellits Type 2 in the Early Stage of the Disease

2006 ◽  
Vol 6 (2) ◽  
pp. 54-58
Author(s):  
Belma Aščić - Buturović
Keyword(s):  
Insulin Therapy ◽  
Pancreatic Beta Cells ◽  
Early Stage ◽  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Target Cells ◽  
Obese Patients ◽  
Patients With Diabetes ◽  
Insulin Activity

Combination of insulin and metformin has been shown to improve glycaemic control in clinical trials, particularly in obese patients with diabetes type 2. Insulin therapy can improve function of pancreatic beta cells and periphery insulin activity in target cells in order to enhance glycaemic homeostasis (1, 2, 3). In our study we included obese patients with diabetes type 2 in the early stage of the disease. The study is partially retrospective and partially prospective. The study encompassed 40 patients split in two groups. The first group of 20 patients received insulin therapy combined with metformin, while the patients of the second group were treated with oral antidiabetic drugs, sulfonylureas and metformin. Three months later, the group treated with insulin and metformin showed improvement in the monitored parameters, namely significant reduction in HbA1c (p = 0.003), MFBG (p = 0.0009), PPG (p = 0.028). Insulin therapy administered together with metformin, in obese patients with diabetes type 2, in the early stage of the disease, resulted in well regulated fasting blood glycaemia, as well as post challenge glycaemia and HbA1c.

scholarly journals THE ROLE OF GUT MICROBIOTA IN PATIENTS WITH DIABETES TYPE 2 AND INSULIN RESISTANCE

2021 ◽  
Author(s):  
Natia Katamadze ◽  
Tamar Kandashvili ◽  
David Metreveli ◽  
David Gordeladze
Keyword(s):  
Diabetes Mellitus ◽  
Gut Microbiota ◽  
Molecular Mechanisms ◽  
Early Stage ◽  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Industrialized Countries ◽  
Common Chronic Disease ◽  
Patients With Diabetes

Diabetes mellitus is one of the most common chronic disease. In a number of developing and industrialized countries, diabetes mellitus has become an epidemic and is one of the leading causes of death. The rapid increase of cases of type 2 diabetes mellitus (T2DM) in the past decades has made it a widespread metabolic disorder. In recent years, an increasing understanding of how our microflora is linked to obesity-related T2DM has provided a new potential target for reducing the risk of T2DM. The aim of our project is to expand our view on the key roles of microflora during the onset and development of T2DM as well as its complications. Our aim was to study 2 groups of people with T2DM and Prediabetes in order to reveal any gastro-intestinal problems. According to questionnaires, it appeared that patients with diabetes type 2 had 3 or more gastrointestinal disorders, 72 % had bloating, 16% constipation and 12% diarrhea. Patients with prediabetes had 3 and more intestinal disorders: 56 % had bloating, 23% constipation and 21 % diarrhea. Despite, multiple studies supporting the importance of gut microbiota in pathophysiology of T2DM, the field is in early stage. Currently, we have reached a point in our understanding that some probiotics and related molecular mechanisms may be involved in glucose metabolism related to T2DM. We should work towards precision/personalized medicine selecting anti-diabetics and probiotics for a given patient to treat patients successfully.

Risk Factors Associated With Hyperuricemia in Patients with Diabetes Type 2: About 190 Cases

2020 ◽  
Vol 2 (1) ◽  
pp. 12-16
Author(s):  
Fennoun H ◽  
Haraj NE ◽  
El Aziz S ◽  
Bensbaa S ◽  
Chadli A
Keyword(s):  
Type 2 Diabetes ◽  
Heart Disease ◽  
Glycemic Control ◽  
Ischemic Heart Disease ◽  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Ischemic Heart ◽  
Factors Associated ◽  
Patients With Diabetes

Introduction: Hyperuricemia is common Type 2 diabetes at very high cardiovascular risk. Objective: Evaluate the relationship between hyperuricemia and diabetes type 2, and determine its predictive factors in this population. Patients and Methods: Retrospective study cross including 190 patients with diabetes type 2 hospitalized Service of Endocrinology of CHU Ibn Rushd Casablanca from January 2015 to December 2017. Hyperuricemia was defined as a serum uric acid concentration> 70 mg/L (men) and> 60 mg/L (women). The variables studied were the anthropometric measurements), cardiovascular factors (tobacco, hypertension, dyslipidemia), and degenerative complications (retinopathy, neuropathy, kidney failure, ischemic heart disease). The analyzes were performed by SPSS software. Results: Hyperuricemia was found in 26.5% of patients with a female predominance (76%), an average age of 55.9 years, and an average age of 12.4ans diabetes. The glycemic control was found in 84.6% of cases with mean glycated hemoglobin 8.6%. Factors associated al hyperuricemia were the blood pressure in 86% (p <0.05), dyslipidemia in 76.3% of cases (p <0.001) with hypertriglyceridemia in 48.3% of cases (p <0.02), and a hypoHDLémie 28% (p <0.001). The age, obesity, smoking, and glycemic control were associated significantly n al hyperuricemia. The research of degenerative complications of hyperuricemia has objectified renal impairment (GFR between 15 and 60ml / min) chez47% (p <0.001), it was kind of moderate in 35.8% (p <0.01) and severe in 5.1% (p <0.02), ischemic heart disease was found in 34% of cases (p <0.01). Conclusion: In our study, hyperuricemia in type 2 diabetes is common in female patients, especially with hypertension, dyslipidemia, and renal failure. Other factors such as age, obesity, smoking is not associated with hyperuricemia in type 2 diabetics.

Efficacy of sodium glucose cotransporter 2 inhibitors as an adjunct treatment for patients with diabetes type 2

2019 ◽  
Vol 152 (11) ◽  
pp. 438-441
Author(s):  
Pedro Pujante ◽  
Jessica Ares ◽  
Carmen Maciá ◽  
Raúl Rodriguez Escobedo ◽  
Edelmiro Menéndez ◽  
...  
Keyword(s):  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Adjunct Treatment ◽  
Sodium Glucose Cotransporter ◽  
Patients With Diabetes

DETECTION OF PULMONARY HYPERTENSION IN COPD PATIENTS WITH DIABETES TYPE 2 (DM2)

CHEST Journal ◽  
2006 ◽  
Vol 130 (4) ◽  
pp. 172S
Author(s):  
Alexander E. Makarevich ◽  
Valentina E. Valevich ◽  
Alexander J. Pochtavcev
Keyword(s):  
Pulmonary Hypertension ◽  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Copd Patients ◽  
Patients With Diabetes
Sign in / Sign up

Export Citation Format

Share Document